Pre-emptive mycophenolate — Competitive Intelligence Brief

Pre-emptive mycophenolate (Pre-emptive mycophenolate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant. Area: Immunology.

phase 3 Immunosuppressant Inosine monophosphate dehydrogenase Immunology Small molecule

Target snapshot

Pre-emptive mycophenolate (Pre-emptive mycophenolate) — University of Bologna. Mycophenolate works by inhibiting inosine monophosphate dehydrogenase, an enzyme crucial for the synthesis of guanosine nucleotides, thereby suppressing lymphocyte proliferation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pre-emptive mycophenolate TARGET	Pre-emptive mycophenolate	University of Bologna	phase 3	Immunosuppressant	Inosine monophosphate dehydrogenase
Azathioprine / 6 Mercaptopurine	Azathioprine / 6 Mercaptopurine	PIBD-Net	marketed	Purine analog immunosuppressant	Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), inosine monophosphate dehydrogenase (IMPDH)
LCP-tacrolimus QD + MMF QD then MMF QD	LCP-tacrolimus QD + MMF QD then MMF QD	University Hospital, Limoges	marketed	Calcineurin inhibitor + antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); inosine monophosphate dehydrogenase type II (MMF)
Mycophenolate Mofetil Cap./Tab.	Mycophenolate Mofetil Cap./Tab.	Chong Kun Dang Pharmaceutical	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor; immunosuppressant	IMPDH type II (inosine monophosphate dehydrogenase)
XR-tacrolimus QD + MMF BID then MMF QD	XR-tacrolimus QD + MMF BID then MMF QD	University Hospital, Limoges	marketed	Calcineurin inhibitor + Antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); Inosine monophosphate dehydrogenase (mycophenolate mofetil)
Azathioprine (AZA)	Azathioprine (AZA)	University Hospital Schleswig-Holstein	marketed	Purine analog immunosuppressant	Inosine monophosphate dehydrogenase (IMPDH), purine synthesis pathway
Ribavirin in Arm 1	Ribavirin in Arm 1	MinaPharm Pharmaceuticals	marketed	Nucleoside analog antiviral	Viral RNA polymerase; IMPDH (inosine monophosphate dehydrogenase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant class)

1. Assistance Publique Hopitaux De Marseille · 1 drug in this class
2. Centre Hospitalier Universitaire, Amiens · 1 drug in this class
3. Hospices Civils de Lyon · 1 drug in this class
4. I.M. Sechenov First Moscow State Medical University · 1 drug in this class
5. Kenya Medical Research Institute · 1 drug in this class
6. Memorial Sloan Kettering Cancer Center · 1 drug in this class
7. National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class
8. Peking Union Medical College Hospital · 1 drug in this class
9. RWTH Aachen University · 1 drug in this class
10. Samsung Medical Center · 1 drug in this class